The Child Neurology Society (CNS) is delighted to welcome UCB, a global biopharmaceutical company focused on creating valuable solutions that improve the lives of people living with neurological and autoimmune conditions, as our newest Mission Partner.
UCB brings extensive expertise in epilepsy management and rare disease innovation, with a focused commitment to advancing understanding and treatment of both epilepsy and the rare genetic mitochondrial disease, Thymidine Kinase 2 Deficiency (TK2d). Their patient-centered approach and dedication to scientific innovation complement CNS’s mission to elevate the standard of care for children with neurological and developmental conditions through robust physician education.
“We welcome UCB as a Mission Partner,” said Monique Terrell, Executive Director and CEO. “UCB’s dual focus on epilepsy and TK2d will provide our members with relevant insights into both established and emerging areas of pediatric neurology. This partnership enhances our ability to deliver comprehensive educational programming that reflects the complex needs of the patients our members serve.”
As a Mission Partner, UCB will support noncommercial educational initiatives that advance member knowledge in epilepsy and TK2d. This partnership reflects our shared commitment to providing child neurologists with resources that enhance their understanding of evolving treatment landscapes and support their ability to deliver quality patient care.
Members can access these resources and learn more about UCB’s commitment to neurology at ucb-usa.com/Disease-Areas/Disease-Areas.